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Sweet’s syndrome (SS) or acute febrile neutrophilic der-
matosis is a rare disorder that often occurs in associa-
tion with other systemic diseases.
The disorder is characterized by development of non-
pruritic, painful erythematous plaques with pseudovesi-
cles, occasional pustules and rare bullae. SS consists of a
triad of erythematous plaques infiltrated by neutrophils
in association with fever and leukocytosis. The patholo-
gical features of SS involve the dermis.
The condition presents in three clinical settings: clas-
sic (or idiopathic) SS, malignancy-associated SS and
drug-induced SS syndrome.
The treatment of choice for SS are systemic corticos-
teroids, although colchicine and potassium iodide are
also considered to be effective for SS.
We present an unusual recurrent course of SS in a
38 year old man who carries compound heterogous
mutations in the MEFV gene.
A 38 year old, generally healthy man from Sephardic
Jewish ancestry, had suddenly developed fever, malaise,
artralgia and painful erythematous plaques with pustules
and bullae on the anterior aspects of the upper extremi-
ties. Diagnostic evaluation included moderate leucocyto-
sis, elevated erythrocyte sedimentation and C-reactive
protein rate and normal liver functions. antistreptolysin
O-titer. Blood cultures and tuberculosis test were nega-
tive. Chest radiography was normal.
The symptoms exacerbated despite treatment with
systemic corticosterids.
Clinical improvement appeared after administration of
colchicine.
Mutational analysis of the MEFV gene revealed com-
pound heterozygous M694V and V726A mutations.
Familial Mediterranean fever (FMF) is an autosomal
recessive disease characterized by recurrent attacks of
fever with serosal inflammation. The FMF gene (MEFV)
encodes the protein pyrin that plays an important role
in modulating the innate immune response.
MEFV mutations have been identified primarily in
patients from Mediterranean populations and in Israel
the carrier state is as high as1: 5.
Sweet’s syndrome has been described in a patient with
classical FMF as a possible new cutaneous feature and
has never been described as a presenting sign of FMF.
Although various skin lesions have been described
with FMF, erysipelas-like erythema (ELE) has been
reported the only pathognomonic cutaneous
manifestation.
Our patient, carrying compound heterozygous muta-
tions in MEFV presented with Sweet’s syndrome.
We suggest, that SS skin lesions might be an only
cutaneous presentation of FMF.
Written informated consent for publication of their
clinical details was obtained from the patient/parent/
guardian/relative of the patient.
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